


RESEARCH REPORT



Immuno-Oncology Diagnostics

Market Forecasts for Immuno-Oncology Diagnostics by Assay Type,
Technology, Client, and Country.
With Executive/Consultant Guides.
2023 to 2027





Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports, and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

1	Market Guides	21
1.1	Situation Analysis	22
1.2	Guide for Executives and Marketing Staff	24
1.3	Guide for Investment Analysts and Management Consultants	25
2	Introduction and Market Definition	26
2.1	What are Immuno-Oncology Diagnostics?	27
2.2	Immuno-oncology – the looming cure	29
2.2.1	Immuno-oncology Diagnostics Takes a Leading Role.....	31
2.3	Market Definition	32
2.3.1	Market Size	32
2.3.2	Currency	32
2.3.3	Years	32
2.4	Methodology	33
2.4.1	Methodology	33
2.4.2	Sources	33
2.4.3	Authors.....	33
2.5	Perspective: Healthcare and the IVD Industry	35
2.5.1	Global Healthcare Spending	35
2.5.2	Spending on Diagnostics	36
2.5.3	Important Role of Insurance for Diagnostics.....	38
3	Immunotherapy – Guide to Immune Technologies	39
3.1	The Immune System	40

3.1.1	Innate immune system	41
3.1.1.1	Surface barriers	42
3.1.1.2	Inflammation	43
3.1.1.3	Complement system	43
3.1.1.4	Cellular barriers	44
3.1.1.5	Natural killer cells	45
3.1.2	Adaptive immune system	46
3.1.2.1	Lymphocytes.....	46
3.1.2.2	Killer T cells	47
3.1.2.3	Helper T cells	49
3.1.2.4	Gamma delta T cells	50
3.1.2.5	B lymphocytes and antibodies	50
3.1.3	Tumor immunology – the immune surveillance system	52
3.2	Immuno Oncology Diagnostics	54
3.2.1	Checkpoint Assays	54
3.2.1.1	Outlook for Checkpoint Assays	58
3.2.2	Cytokine Assays	59
3.2.2.1	Outlook for Cytokine Assays	60
3.2.3	Genomic Germline.....	60
3.2.3.1	Outlook for Genomic Germline	61
3.2.4	Genomic Tumour	61
3.2.4.1	Outlook for Genomic Tumour.....	64
3.2.5	Tumor Microenviroment	65
3.2.5.1	Outlook for Tumor Microenvironment	66
3.2.6	Others.....	66

3.2.6.1	Outlook for Other Diagnostics.....	66
4	Industry Overview.....	67
4.1	Players in a Dynamic Market.....	68
4.1.1	Academic Research Lab.....	69
4.1.2	Diagnostic Test Developer.....	69
4.1.3	Instrumentation Supplier.....	70
4.1.4	Chemical/Reagent Supplier.....	70
4.1.5	Pathology Supplier.....	70
4.1.6	Independent Clinical Laboratory.....	71
4.1.7	Public National/regional Laboratory.....	71
4.1.8	Hospital Laboratory.....	72
4.1.9	Physicians Office Lab (POLs).....	72
4.1.10	Audit Body.....	73
4.1.11	Certification Body.....	73
5	Market Trends.....	75
5.1	Factors Driving Growth.....	76
5.1.1	Outcome potential.....	76
5.1.2	Companion Diagnostics.....	77
5.1.3	Funding.....	77
5.1.4	Technology Environment.....	77
5.1.5	Target Solutions.....	78
5.2	Factors Limiting Growth.....	79
5.2.1	Complex Role of Diagnostics.....	79
5.2.2	Clinical Trials Role.....	80
5.2.3	Protocols.....	80

5.3	Diagnostic Technology Development	81
5.3.1	Combinations - Issues and Complexity	81
5.3.2	Shifting Role of Diagnostics.....	83
5.3.3	Multiplexing and Foundation One.....	84
5.3.4	The Disruption Dynamic	85
5.3.5	The Race for Biomarkers	85
5.3.6	The Next Five Years.....	86
6	Cancer Immuno-Oncology Diagnostics Recent Developments	87
6.1	Recent Developments – Importance and How to Use This Section	88
6.1.1	Importance of These Developments.....	88
6.1.2	How to Use This Section.....	88
6.2	Lung Cancer Data Heralds Shift for Hummingbird Dx	88
6.3	PamGene Awarded €7.5M for Immunotherapy Test	92
6.4	Freenome Acquires Oncimmune	92
6.5	Guardant Health Gets Coverage for Liquid Biopsy Treatment Response Test	93
6.6	BostonGene to Develop Sarcoma-Specific Liquid Biopsy	94
6.7	Exact Sciences OncoExTra Therapy Selection Test.....	95
6.8	Integrated DNA Technologies Buys NGS Research Assays.....	97
6.9	Navignostics Using Single-Cell Spatial Proteomics.....	98
6.10	New Reference Samples for NGS-Based Cancer Tests	102
6.11	Spatial Proteomics Panel for Immuno-Oncology.....	103
6.12	dMMR, MSI Assays for Immunotherapy Patient Selection.....	103
6.13	OncoHost Expands Prophet Platform Research	109
6.14	Protein-Based Liquid Biopsy Panel Assesses TME.....	109
6.15	Oncimmune Announces Sixfold Revenue Increase	113

6.16	Mayo Clinic, Personalis Ink Collaboration.....	114
6.17	Lucence Liquid Biopsy Test Tracks Immune Treatment ctDNA Changes	116
6.18	Qiagen, OncXerna Close Companion Dx Development Deal.....	119
6.19	Natera Test to Guide Therapy for Bladder Cancer	120
6.20	Veracyte Halio Acquisition to Boost Immuno-oncology Activity	123
6.21	Freenome Eyes New Dx Possibilities.....	125
6.22	Oncocyte Data has Potential as Immunotherapy Response Predictor	128
6.23	OncoDNA use HalioDx to Expand into North America	132
6.24	Adaptive Biotechnologies, Q2 Solutions Agreement for ImmunoSeq Assay .	133
6.25	Qiagen Expands Immuno-Oncology Portfolio	134
6.26	Immune Profiling System Redirected to Fight COVID-19.....	135
6.27	IncellDx Awarded PD-L1 Detection Patent	137
6.28	FDA Approves CDx for Trastuzumab	138
6.29	Promega Nabs CE Mark for Microsatellite Instability IVD	139
6.30	ArcherDx partners with AstraZeneca for Immuno-Oncology	140
6.31	Germline Results Guides Precision Therapy	141
6.32	Agilent PD-L1 Assay Gets FDA Approval.....	145
6.33	Bayer, OrigiMed Form Companion Diagnostic Development Alliance	146
6.34	Bio-Me to Develop Microbiome Biomarker Test for Cancer Immunotherapy	146
6.35	SkylineDx, BioInvent Collaborate to Characterize Predictive Immunological Signatures	147
6.36	Biocare Medical Launches 7 Novel IVD Antibodies.....	148
7	Profiles of Key Immuno-oncology Companies	150
7.1	10x Genomics, Inc.....	151
7.2	Abbott Laboratories.....	152

7.3	AccuraGen Inc.....	153
7.4	Aethlon Medical.....	155
7.5	Agilent/Dako	156
7.6	Anchor Dx	158
7.7	ANGLE plc	159
7.8	AVIVA Systems Biology	161
7.9	Baylor Miraca Genetics Laboratories.....	162
7.10	Becton, Dickinson and Company	164
7.11	Berkley Lights.....	166
7.12	BGI Genomics Co. Ltd	167
7.13	Bioarray Genetics.....	169
7.14	Biocartis	170
7.15	Biocept, Inc.....	171
7.16	Biodesix Inc.	172
7.17	BioFluidica	173
7.18	BioGenex.....	174
7.19	BioIVT	175
7.20	Biolidics Ltd.....	176
7.21	bioMérieux Diagnostics.....	177
7.22	Bioneer Corporation	179
7.23	Bio-Rad Laboratories, Inc.	180
7.24	Bio-Reference Laboratories.....	182
7.25	Bio-Techne	183
7.26	Bioview	184
7.27	Bolidics.....	185

7.28	Boreal Genomics.....	186
7.29	Bristol-Myers Squibb.....	187
7.30	Burning Rock.....	188
7.31	Cardiff Oncology	189
7.32	Caris Molecular Diagnostics.....	190
7.33	Castle Biosciences, Inc.	191
7.34	CellCarta.....	192
7.35	CellMax Life	193
7.36	Cepheid (Danaher)	194
7.37	Charles River Laboratories.....	196
7.38	Circulogene	197
7.39	Cizzle Biotech.....	198
7.40	Clinical Genomics	199
7.41	Cytolumina Technologies Corp.....	200
7.42	Datar Cancer Genetics Limited	201
7.43	Diagnologix LLC.....	202
7.44	Diasorin S.p.A.	203
7.45	Dxcover	205
7.46	Element Biosciences	206
7.47	Enzo Biochem	207
7.48	Epic Sciences.....	208
7.49	Epigenomics AG.....	209
7.50	Eurofins Scientific	210
7.51	Fabric Genomics.....	212
7.52	Fluxion Biosciences.....	213

7.53	Freenome.....	214
7.54	FUJIFILM Wako Diagnostics.....	215
7.55	Fyr Diagnostics.....	216
7.56	GeneFirst Ltd.	217
7.57	Genetron Holdings.....	218
7.58	GenomOncology.....	219
7.59	GILUPI Nanomedizin.....	220
7.60	Guardant Health.....	221
7.61	HansaBiomed.....	222
7.62	HeiScreen.....	223
7.63	Helomics.....	224
7.64	HTG Molecular Diagnostics.....	225
7.65	iCellate.....	226
7.66	ICON PLC.....	227
7.67	Illumina.....	228
7.68	Incell Dx.....	229
7.69	Inivata.....	230
7.70	INOVIQ.....	231
7.71	Integrated Diagnostics.....	232
7.72	Invitae Corporation.....	233
7.73	Invivogen.....	234
7.74	Invivoscribe.....	235
7.75	Janssen Diagnostics.....	236
7.76	Lunglife AI Inc.....	237
7.77	MDNA Life SCIENCES, Inc.	238

7.78	MDx Health	239
7.79	Menarini Silicon Biosystems.....	240
7.80	Mesa Laboratories, Inc.	241
7.81	Millipore Sigma	242
7.82	Miltenyi Biotec	243
7.83	miR Scientific.....	244
7.84	Myriad Genetics/Myriad RBM	245
7.85	NantHealth, Inc.	246
7.86	Natera	247
7.87	NeoGenomics	248
7.88	NGeneBio.....	249
7.89	Novogene Bioinformatics Technology Co., Ltd.	251
7.90	Oncocyte.....	253
7.91	OncoDNA.....	254
7.92	Ortho Clinical Diagnostics	255
7.93	Oxford Nanopore Technologies	256
7.94	PamGene.....	257
7.95	Panagene	258
7.96	Perkin Elmer (Revvity)	259
7.97	Personal Genome Diagnostics	260
7.98	Personalis.....	261
7.99	Precipio	262
7.100	Precision Medicine Group	263
7.101	PrecisionMed.....	264
7.102	Predicine.....	265

7.103	Promega.....	266
7.104	Qiagen.....	268
7.105	Rarecells SAS	270
7.106	RareCyte	271
7.107	Roche Molecular Diagnostics	272
7.108	ScreenCell.....	274
7.109	Sense Biodetection.....	275
7.110	Siemens Healthineers	276
7.111	simfo GmbH.....	277
7.112	Singlera Genomics Inc.	278
7.113	Singular Genomics.....	279
7.114	Singulomics.....	280
7.115	SkylineDx	281
7.116	Standard BioTools	282
7.117	Stilla Technologies.....	283
7.118	Sysmex Inostics	284
7.119	Tempus Labs, Inc.	285
7.120	Thermo Fisher Scientific Inc.	286
7.121	Todos Medical.....	288
7.122	Ultima Genomics	289
7.123	Veracyte.....	290
7.124	Volition	291
7.125	Vortex Biosciences.....	292
8	The Global Market for Immuno-Oncology Diagnostics	293
8.1	Global Market Overview by Country	294

8.1.1	Table – Global Market by Country.....	294
8.1.2	Chart - Global Market by Country.....	295
8.2	Global Market by Assay Type - Overview.....	296
8.2.1	Table – Global Market by Assay Type	296
8.2.2	Chart – Global Market by Assay Type – Base/Final Year Comparison.....	297
8.2.3	Chart – Global Market by Assay Type – Base Year	298
8.2.4	Chart – Global Market by Assay Type – End Year.....	299
8.2.5	Chart – Global Market by Assay Type – Share by Year	300
8.2.6	Chart – Global Market by Assay Type – Segments Growth.....	301
8.3	Global Market by Technology - Overview	302
8.3.1	Table – Global Market by Technology	302
8.3.2	Chart – Global Market by Technology – Base/Final Year Comparison	303
8.3.3	Chart – Global Market by Technology – Base Year.....	304
8.3.4	Chart – Global Market by Technology – End Year.....	305
8.3.5	Chart – Global Market by Technology – Share by Year	306
8.3.6	Chart – Global Market by Technology – Segments Growth	307
8.4	Global Market by Customer - Overview.....	308
8.4.1	Table – Global Market by Customer.....	308
8.4.2	Chart – Global Market by Customer – Base/Final Year Comparison.....	309
8.4.3	Chart – Global Market by Customer – Base Year	310
8.4.4	Chart – Global Market by Customer – End Year	311
8.4.5	Chart – Global Market by Customer – Share by Year	312
8.4.6	Chart – Global Market by Customer – Segments Growth.....	313
9	Global Immuno-Oncology Diagnostic Markets – By Application.....	314
9.1	Checkpoint.....	315

9.1.1	Table Checkpoint – by Country	315
9.1.2	Chart - Checkpoint Growth.....	316
9.2	Cytokine	317
9.2.1	Table Cytokine – by Country	317
9.2.2	Chart - Cytokine Growth.....	318
9.3	Germline Genetic	319
9.3.1	Table Germline Genetic – by Country.....	319
9.3.2	Chart - Germline Genetic Growth	320
9.4	Genetic Tumor.....	321
9.4.1	Table Genetic Tumor – by Country	321
9.4.2	Chart - Genetic Tumor Growth	322
9.5	Tumor Microenvironment	323
9.5.1	Table Tumor Microenvironment – by Country	323
9.5.2	Chart – Tumor Microenvironment Growth	324
9.6	Other	325
9.6.1	Table Other – by Country.....	325
9.6.2	Chart - Other Growth	326
10	Global Immuno-Oncology Diagnostic Markets – By Technology.....	327
10.1	NGS.....	328
10.1.1	Table NGS – by Country	328
10.1.2	Chart - NGS Growth.....	329
10.2	PCR	330
10.2.1	Table PCR – by Country.....	330
10.2.2	Chart - PCR Growth	331
10.3	Fish/IHC.....	332

10.3.1	Table Fish/IHC – by Country	332
10.3.2	Chart - Fish/IHC Growth.....	333
10.4	Chem/IA.....	334
10.4.1	Table Chem/IA – by Country	334
10.4.2	Chart - Chem/IA Growth.....	335
10.5	Other Technology	336
10.5.1	Table Other Technology – by Country.....	336
10.5.2	Chart – Other Technology Growth.....	337
11	Global Immuno-Oncology Diagnostic Markets – By Customer	338
11.1	Pharma.....	339
11.1.1	Table Pharma – by Country	339
11.1.2	Chart - Pharma Growth.....	340
11.2	Clinic.....	341
11.2.1	Table Clinic – by Country	341
11.2.2	Chart - Clinic Growth.....	342
11.3	Other Customer Genetic.....	343
11.3.1	Table Other Customer – by Country	343
11.3.2	Chart - Other Customer Growth.....	344
12	Appendices.....	345
12.1	Growth of Approved IVD Test Menu	346
12.2	Prevalence of Cancer Treatments.....	347
12.3	United States Medicare System: Clinical Laboratory Fees Schedule	348
12.4	The Most Used IVD Assays.....	440
12.5	The Highest Grossing Assays.....	445

Table of Tables

Table 1 List of Cancers by Mortality	30
Table 2 Overview of Innate and Adaptive Immunity	41
Table 3 FDA Approved Monoclonal Antibodies in Cancer treatment	55
Table 4 FDA Approved Companion diagnostics in Cancer treatment	62
Table 5 Market Players by Type	69
Table 6 Five Factors Driving Growth	76
Table 7 Three Factors Limiting Growth.....	79
Table 8 - Global Market by Region.....	294
Table 9 Global Market by Assay Type	296
Table 10 Global Market by Technology	302
Table 11 Global Market by Customer	308
Table 12 Checkpoint by Country	315
Table 13 Cytokine by Country	317
Table 14 Germline Genetic by Country	319
Table 15 Genetic Tumor by Country.....	321
Table 16 Tumor Microenvironment by Country	323
Table 17 Other by Country	325
Table 18 NGS by Country.....	328
Table 19 PCR by Country	330
Table 20 Fish/IHC by Country	332
Table 21 Chem/IA by Country	334
Table 22 Other Technology by Country	336
Table 23 Pharma by Country.....	339

Table 24 Clinic by Country.....341

Table 25 Other Customer by Country.....343

Table 26 2022 Clinical Lab Fee Schedule.....348

Table 27 The Most Common Assays440

Table 28 Largest Revenue Assays445

Table of Figures

Figure 1 Cancer Death Rates – USA, CDC	29
Figure 2 Global healthcare Spending	36
Figure 3 The Lab Test Pie	37
Figure 4 Helper T Cell Roles	49
Figure 5 Antibody Diagram	51
Figure 6 Macrophages attack a Cancer Cell	52
Figure 7 The Tumour Micro Environment.....	65
Figure 8 The Road to Diagnostics.....	68
Figure 9 Comparing IO Diagnostic and Traditional Testing.....	83
Figure 10 Growth rates of IO Diagnostic Technologies.....	86
Figure 11 Global Market Density Chart	295
Figure 12 Global Market by Assay Type - Base vs. Final.....	297
Figure 13 Global Market by Assay Type Base Year	298
Figure 14 Global Market by Assay Type End Year.....	299
Figure 15 Assay Type Share by Year	300
Figure 16 Assay Type Segments Growth.....	301
Figure 17 Global Market by Technology - Base vs. Final	303
Figure 18 Global Market by Technology Base Year.....	304
Figure 19 Global Market by Technology End Year	305
Figure 20 Technology Share by Year	306
Figure 21 Technology Segments Growth	307
Figure 22 Global Market by Customer - Base vs. Final.....	309

Figure 23 Global Market by Customer Base Year	310
Figure 24 Global Market by Customer End Year	311
Figure 25 Customer Share by Year	312
Figure 26 Customer Segments Growth.....	313
Figure 27 Checkpoint Growth	316
Figure 28 Cytokine Growth	318
Figure 29 Germline Genetic Growth	320
Figure 30 Genetic Tumor Growth.....	322
Figure 31 Tumor Microenvironment Growth	324
Figure 32 Other Growth.....	326
Figure 33 NGS Growth	329
Figure 34 PCR Growth	331
Figure 35 Fish/IHC Growth.....	333
Figure 36 Chem/IA Growth.....	335
Figure 37 Other Technology Growth	337
Figure 38 Pharma Growth.....	340
Figure 39 Clinic Growth.....	342
Figure 40 Other Customer Growth.....	344
Figure 41 IVD Test Menu Growth 2011-2022	346
Figure 42 Prevalence of Cancer Treatments.....	347